Pfizer Biologics’ Clinical Manufacturing Facility, Massachusetts, United States of America


Pfizer Biologics' manufacturing facility

Pfizer began construction of a new biologics clinical manufacturing facility at its existing manufacturing facility located at Andover, Massachusetts, US, in June 2016. The new facility will be used for the production high-quality, complex biologics and vaccines. It is expected to come on stream by January 2019.

Estimated to cost $200m, the project will create 200 construction jobs, and 75 new job opportunities for people to support clinical manufacturing. It will have clinical manufacturing options designed to provide the low cost and greatest flexibility for efficiently driving new treatments to patients.

Details of Pfizer's new biological clinical manufacturing facility

The new facility will be a five-storey building with a total floor space of 175,000ft². It is designed to have five independent manufacturing suites to support Pfizer's highly complex and diverse biologics research effort.

It will be equipped with flexible design to fully enable next-generation manufacturing strategies, and will use sophisticated single-use bioreactors and disposable process technologies.

Location details

The new biological clinical manufacturing facility is being built as an expansion to Pfizer's existing manufacturing facility located in Andover campus in Massachusetts. The new facility will provide added capacity to produce complex biologics and vaccines with the new building.

The Andover facility is spread over in a 70-acre campus, which has seven buildings equipped with laboratories, clinical and commercial manufacturing suites and support areas. It also includes purification facilities and a clinical drug product manufacturing facility.

Andover is located in a strategically integrated site, which serves as an essential part in both Pfizer's research and development (R&D) and global supply network. It has both R&D and flexible, multi-product manufacturing capabilities facilities. It is a hub for R&D in Cambridge and has approximately 2,000 employees based in Massachusetts.

Massachusetts attracted a major investment from pharmaceutical companies including Bristol-Myers Squibb's $280m plant in Devens and several other firms opening up research centres in Cambridge.

Products manufactured at Pfizer's Andover facility

The new facility will be used for the production of vaccines as well as complex biologics, including BeneFIX®, Coagulation Factor IX (Recombinant) and bone morphogenetic protein (rhBMP). It will also produce polysaccharides, components of Prev(e)nar-13, and Pneumococcal 13-valent Conjugate Vaccine (Diptheria CRM197 Protein).

"The new facility will be used for the production high-quality, complex biologics and vaccines."

The Andover facility's building B was approved as a multi-product facility that can allow clinical and commercial products to be produced simultaneously and was also designated as the launch site for Pfizer's mAb drug substances.

Tax benefits

The Town of Andover approved a five-year tax-increment financing agreement for Pfizer at its annual town meeting held in May 2016. According to the agreement, Pfizer will pay tax at the current value for the first three years, and at 65% of value for fourth and fifth years regardless of increase in property value due to the new facility.

As a result, Pfizer will get approximately $2.9m in tax breaks, while generating roughly $3.9m in tax savings for Andover over ten years.

Marketing commentary on Pfizer

Pfizer is a global pharmaceutical company with headquarters in New York, US. It is engaged in the discovery, development and manufacture of healthcare products. It develops and manufactures medicines and vaccines for a wide range of medical disciplines including immunology, oncology, cardiology, diabetology and neurology.

Its global portfolio includes medicines and vaccines as well as many of the well-known consumer healthcare products.

A major part of Pfizer's revenue comes from the vaccine business, which is mainly driven by strong uptake of its pneumococcal vaccine Prevnar 13.